On May 18, 2020, Simcere announced the collaboration with Primary Peptides, a privately held biotech company in Canada, on exclusive license to develop and commercialize an innovative product for the treatment of stroke.
Under the agreement, Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan, while Primary Peptides retains rights in all other markets.
“Simcere is pleased to collaborate with Primary Peptides, a world leader in development of innovative peptide therapeutics”, commented Dr. Peng Wang, Senior VP of Simcere, "Simcere keeps looking for innovative research around the world and this partnership opportunity definitely will help us develop better and more effective therapies for stroke patients.”
Dr. Max Cynader, CEO of Primary Peptides, said “Simcere is a large pharmaceutical company with a proven track record of business success and clinical development leadership and we are excited to form this exclusive partnership for a new therapeutic with Simcere in China. Brain protection following stroke represents a large unmet medical need, and this new peptide therapeutic has the potential to improve the lives of many stroke victims.”